Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712920 | 0.89 | PDK2 (0.39) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL1712647 | 0.87 | PDK2 (0.41) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL6195462 | 0.84 | PTGER4 (0.37) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL6195464 | 0.84 | PTGER4 (0.37) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL1712652 | 0.83 | PDK2 (0.39) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL14092774 | 0.83 | PTGER4 (0.53) | PTGER4PTGER3PTGER2MEN1POLB | |
| SCHEMBL3682030 | 0.83 | PTGER4 (0.39) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL6437112 | 0.83 | PTGER4 (0.39) | PTGER4PTGER3PTGER2PDK2BRD4 | |
| SCHEMBL11624805 | 0.79 | PTGER4 (0.59) | PTGER4PTGER3PTGER2 | |
| SCHEMBL8486360 | 0.79 | PDK2 (0.36) | PTGER4PTGER3PTGER2PDK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | PTGER4 1125/4885PTGER3 1257/4885PTGER2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.